jbrower

Thank you Sara, and all of the other presenters, for the excellent information given during the teleconference. I look forward to listening in on future presentations.

I withdrew my question at the last moment because it was really along the same lines of what Esther had just finished asking. I'll reword my question here, in case Dr. Harbour or anyone else has additional info to respond with:

Heterogeneity within the tumor environment is well-established, so my question was related to how sure we are that a FNAB is representative of the tumor as a whole. Dr. Harbour briefly mentioned that looking at specific gene mutations (eg. BAP1) is prone to sampling error from this heterogeneity, but that he felt more confident looking at a genetic profile (eg. the small array of genes included in the Castle Biosciences DecisionDx-UM assay). Has anyone investigated whether this genetic profile is in fact consistent across an entire tumor that is known to be heterogeneous for a BAP1 mutation?

Similarly, I was going to ask how the Castle gene array relates to BAP1, but again Dr. Harbour sort of touched on why he prefers to look at more than a single mutation. Is it known how a Class 1A/1B/2 designation correlates with a BAP1 mutation?

Happy Holidays to all,

Jeremy Brower

Thank you Sara, and all of the other presenters, for the excellent information given during the teleconference. I look forward to listening in on future presentations.

I withdrew my question at the last moment because it was really along the same lines of what Esther had just finished asking. I'll reword my question here, in case Dr. Harbour or anyone else has additional info to respond with:

Heterogeneity within the tumor environment is well-established, so my question was related to how sure we are that a FNAB is representative of the tumor as a whole. Dr. Harbour briefly mentioned that looking at specific gene mutations (eg. BAP1) is prone to sampling error from this heterogeneity, but that he felt more confident looking at a genetic profile (eg. the small array of genes included in the Castle Biosciences DecisionDx-UM assay). Has anyone investigated whether this genetic profile is in fact consistent across an entire tumor that is known to be heterogeneous for a BAP1 mutation?

Similarly, I was going to ask how the Castle gene array relates to BAP1, but again Dr. Harbour sort of touched on why he prefers to look at more than a single mutation. Is it known how a Class 1A/1B/2 designation correlates with a BAP1 mutation?

Happy Holidays to all,

Jeremy Brower

Thank you Sara, and all of the other presenters, for the excellent information given during the teleconference. I look forward to listening in on future presentations.

I withdrew my question at the last moment because it was really along the same lines of what Esther had just finished asking. I'll reword my question here, in case Dr. Harbour or anyone else has additional info to respond with:

Heterogeneity within the tumor environment is well-established, so my question was related to how sure we are that a FNAB is representative of the tumor as a whole. Dr. Harbour briefly mentioned that looking at specific gene mutations (eg. BAP1) is prone to sampling error from this heterogeneity, but that he felt more confident looking at a genetic profile (eg. the small array of genes included in the Castle Biosciences DecisionDx-UM assay). Has anyone investigated whether this genetic profile is in fact consistent across an entire tumor that is known to be heterogeneous for a BAP1 mutation?

Similarly, I was going to ask how the Castle gene array relates to BAP1, but again Dr. Harbour sort of touched on why he prefers to look at more than a single mutation. Is it known how a Class 1A/1B/2 designation correlates with a BAP1 mutation?

Happy Holidays to all,

Jeremy Brower